Get the Stockscreener App
20.98
1.64%
-0.335
Genmab Adr stock is traded at $20.98, with a volume of 484.15K.
It is down -1.64% in the last 24 hours and down -0.85% over the past month.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$21.32
Open:
$21.14
24h Volume:
484.15K
Relative Volume:
0.34
Market Cap:
$1.34B
Revenue:
$2.62B
Net Income/Loss:
$966.70M
P/E Ratio:
13.99
EPS:
1.5004
Net Cash Flow:
$1.09B
1W Performance:
+0.77%
1M Performance:
-0.85%
6M Performance:
-2.47%
1Y Performance:
-25.08%
1-Day Range:
$20.57
$21.18
1-Week Range:
$20.57
$21.41
52-Week Range:
$17.23
$28.96
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
20.98 | 12.95B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
ONC
Beone Medicines Ltd Adr
|
247.11 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.43 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.55 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.53 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-25 | Downgrade | Bernstein | Mkt Perform → Underperform |
| Mar-11-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-13-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-20-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-15-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-23-24 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Dec-06-23 | Upgrade | UBS | Neutral → Buy |
| Nov-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-08-23 | Upgrade | DNB Markets | Sell → Buy |
| Oct-18-23 | Initiated | Exane BNP Paribas | Underperform |
| Sep-06-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-24-23 | Initiated | BTIG Research | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-31-23 | Initiated | UBS | Neutral |
| May-12-23 | Initiated | Morgan Stanley | Underweight |
| Dec-20-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-14-22 | Initiated | William Blair | Mkt Perform |
| Nov-11-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
| May-02-22 | Initiated | Cowen | Market Perform |
| Mar-16-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-01-21 | Initiated | Berenberg | Sell |
| Sep-16-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-24-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Jan-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-20 | Downgrade | Bryan Garnier | Neutral → Sell |
| Sep-08-20 | Initiated | SVB Leerink | Mkt Perform |
| Jun-25-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-23-20 | Initiated | Credit Suisse | Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Sep-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | Morgan Stanley | Overweight |
| Aug-12-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Genmab Adr Stock (GMAB) Latest News
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Applied Dna Sciences Inc (APDN)’s Day in Review: Closing at 0.85, Down by -2.41 - DWinneX
Stock Surge: Genmab ADR (GMAB) Closes at 19.42, Marking a -5.73 Increase/Decrease - DWinneX
Market Momentum Report: Evercore Inc (EVR)’s Positive Close at 216.74 - DWinneX
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) - GlobeNewswire Inc.
Investing in Take-Two Interactive Software, Inc (TTWO) Is Getting More Attractive - knoxdaily.com
Investing in Genmab ADR (GMAB): What You Must Know - knoxdaily.com
Nucor Corp (NUE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
EWTX Stock Sees Surge of Approximately 4.24% in Last Five Days - knoxdaily.com
GMAB or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance
Genmab ADR (NASDAQ: GMAB) Jumps 1.19% In Recent Session. Here’s Everything You Need To Know. - Stocksregister
AGCO Corp (AGCO) Beta Value: Understanding the Market Risk - News Heater
Evercore Inc’s Mixed Bag: Down -29.24% in 6 Months, Down -20.22% in 30 Days - investchronicle.com
GMAB’s Debt-to-Equity Ratio at 0.03: What It Means for Genmab ADR’s Future - investchronicle.com
CZR Stock Sees Decline of Approximately -4.82% in Last Five Days - knoxdaily.com
Magnite Inc (MGNI) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
DLocal Limited (DLO) Shares Decline Despite Market Challenges - The News Heater
Genmab ADR Inc. (GMAB) Price Performance: The Role of Supply and Demand - The InvestChronicle
Views of Wall Street’s Leading Experts on Genmab ADR - SETE News
What is Core & Main Inc (CNM) Stock Return on Shareholders’ Capital? - SETE News
There is no doubt that Kite Realty Group Trust (KRG) ticks all the boxes. - SETE News
Sea Ltd ADR (NYSE: SE) Jumps 4.64%, Turning Investors Away - Stocks Register
Does Genmab ADR (NASDAQ: GMAB) Still Look Hot This Week? - Stocks Register
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN
GMAB vs. QGEN: Which Stock Is the Better Value Option? - MSN
Are Investors Undervaluing Genmab (GMAB) Right Now? - Yahoo Finance
Genmab stock holds Buy rating on positive trial results - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Weekly Upgrades and Downgrades - InvestorPlace
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? - Yahoo Finance
Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance
RBC Capital upgrades Genmab stock amid strong pipeline prospects - Investing.com
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance
Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily
GMAB: Bank on the Future Returns With These 3 Biotech Stocks - StockNews
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results - MarketWatch
Genmab ADR Getting Closer To Key Technical Measure - Investor's Business Daily
Stocks Flashing Renewed Technical Strength: Ascendis Pharma ADR - Investor's Business Daily
GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo News Canada
New Strong Buy Stocks for January 11th - Yahoo Finance
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates - Yahoo
INCY vs. GMAB: Which Stock Is the Better Value Option? - Yahoo Finance
Genmab Adr Stock (GMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):